Europe Yellow Fever Vaccines Market to Witness 6.4% CAGR by 2031

Europe Yellow Fever Vaccines Market 2025 - 2031 : Size, Trends, Overview

Executive Summary

The Yellow Fever Vaccines Market is expected to experience steady growth from 2025 to 2031, driven by an increasing global focus on yellow fever prevention, the expanding travel and tourism industry, and improvements in vaccine distribution networks. The market is anticipated to grow at a CAGR of 6.4% over this forecast period, reaching a value of approximately USD 2.3 billion by 2031. Key drivers include the growing incidence of yellow fever outbreaks, government and WHO-backed vaccination initiatives, and enhanced vaccine formulations.

1. Introduction to Yellow Fever and Yellow Fever Vaccines

What is Yellow Fever?

Yellow fever is a viral hemorrhagic disease transmitted by mosquitoes, specifically the Aedes and Haemagogus species. The disease is prevalent in tropical and subtropical regions of Africa and South America. Yellow fever is characterized by symptoms such as:

• Fever

• Jaundice (yellowing of the skin and eyes)

• Fatigue

• Muscle pain

• Vomiting and bleeding (in severe cases)

In severe cases, yellow fever can cause liver damage, kidney failure, and death. Yellow fever is preventable through vaccination, which has been one of the most successful public health interventions in regions at risk.

Role of Vaccines in Yellow Fever Prevention

The Yellow Fever Vaccine is a live-attenuated vaccine, which means it contains a weakened form of the yellow fever virus. The vaccine is highly effective in preventing yellow fever and provides long-lasting immunity with a single dose. The yellow fever vaccination is recommended for individuals living in or traveling to areas where the disease is endemic.

Vaccination is the most effective way to control yellow fever outbreaks and prevent the spread of the disease. According to the World Health Organization (WHO), the yellow fever vaccine is part of the routine immunization schedule for infants in endemic areas, and a single dose provides lifelong immunity.

Request Sample Report @ https://www.marketreportsinsights.com/sample/134247 

2. Market Dynamics

Market Drivers

1. Rising Yellow Fever Outbreaks

   • Yellow fever outbreaks continue to occur in endemic regions, such as Sub-Saharan Africa and South America. These outbreaks have raised awareness about the importance of vaccination, driving demand for yellow fever vaccines. For instance, recent outbreaks in Brazil, Uganda, and Angola have highlighted the need for efficient vaccination strategies.

2. Government and International Health Initiatives

   • Governments, in collaboration with international organizations such as the World Health Organization (WHO) and UNICEF, are focusing on increasing yellow fever vaccination coverage to control outbreaks and eliminate the disease. The Global Vaccine Safety Initiative and Eliminate Yellow Fever Epidemics (EYE) Strategy aim to provide the vaccine to millions of people in endemic areas, particularly during vaccination campaigns.

3. Increase in International Travel

   • The rise in international travel has contributed to the spread of yellow fever, prompting more individuals to seek vaccination before traveling to high-risk areas. Many countries have mandatory vaccination requirements for travelers arriving from yellow fever-endemic regions, thereby boosting demand for the vaccine.

4. Strong Focus on Preventive Healthcare

   • There is an increasing global focus on preventive healthcare, with vaccination being a key part of public health strategies to prevent infectious diseases. This trend is expected to positively impact the market for yellow fever vaccines.

5. Technological Advancements in Vaccine Production

   • Advances in vaccine manufacturing, including improvements in stability and storage, are enabling the production of more affordable and accessible yellow fever vaccines. Innovations in vaccine delivery systems and cold chain logistics are improving the availability of vaccines in remote and underserved regions.

Market Restraints

1. Vaccine Hesitancy

   • Vaccine hesitancy, driven by misinformation and distrust in vaccines, is a significant challenge in some regions. Despite the proven effectiveness of the yellow fever vaccine, there are communities where public reluctance to vaccinate remains a barrier to achieving herd immunity.

2. Logistical Challenges in Distribution

   • The distribution of yellow fever vaccines in remote and low-income areas can be hindered by logistical challenges, including cold chain requirements and limited healthcare infrastructure. These issues can delay vaccination campaigns and prevent vaccines from reaching the populations that need them most.

3. Cost of Vaccines in Low-Income Countries

   • Although yellow fever vaccines are relatively inexpensive, the cost of large-scale vaccination campaigns in low-income countries can be a significant barrier. Continued efforts from organizations such as GAVI, the Vaccine Alliance, are required to subsidize vaccines and ensure their affordability for underserved populations.

4. Regulatory and Policy Issues

   • Vaccine approval processes and regulatory requirements vary by region, which can slow the introduction of new vaccine formulations or prevent the rapid rollout of vaccines during outbreaks.

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://www.marketreportsinsights.com/industry-forecast/yellow-fever-vaccines-market-2022-134247 

3. Market Segmentation

By Vaccine Type

1. Live-Attenuated Yellow Fever Vaccine

   • The live-attenuated yellow fever vaccine is the most widely used and recommended form of vaccination. It provides lifelong immunity with a single dose and is considered highly effective. This form of vaccine is commonly administered in both endemic areas and for travelers to high-risk regions.

2. Inactivated Yellow Fever Vaccine

   • While live-attenuated vaccines dominate the market, research is ongoing into the development of inactivated vaccines or alternatives for individuals who cannot receive live vaccines due to immunocompromised states. However, the market share for inactivated vaccines remains limited compared to live-attenuated options.

By End-User

1. Hospitals and Healthcare Providers

   • Hospitals and healthcare clinics serve as the primary point of access for yellow fever vaccines, especially for travelers and high-risk individuals. Healthcare providers play a key role in administering vaccines and managing outbreaks.

2. Public Health Campaigns and Vaccination Drives

   • International organizations, governments, and non-governmental organizations (NGOs) are responsible for organizing large-scale vaccination campaigns, especially in areas experiencing outbreaks or those with low vaccination coverage. These campaigns are crucial for boosting vaccine uptake in endemic regions.

3. Pharmacies and Clinics

   • Pharmacies and travel clinics are increasingly becoming important distribution points for yellow fever vaccines, especially for travelers needing pre-departure vaccinations.

By Region

1. North America

   • North America is a major consumer of yellow fever vaccines, with travelers to endemic regions requiring vaccinations before travel. Additionally, the U.S. and Canada have regulations requiring proof of vaccination for travelers arriving from yellow fever-endemic areas.

2. Europe

   • In Europe, the demand for yellow fever vaccines is driven by the need for vaccinations among travelers to endemic areas, as well as ongoing immunization efforts in African and South American countries supported by European governments and organizations.

3. Africa

   • Africa is the epicenter of yellow fever transmission, with countries such as Nigeria, Democratic Republic of Congo (DRC), and Uganda experiencing periodic outbreaks. Efforts to increase vaccination coverage in this region are a significant driver of market growth.

4. South America

   • South America, especially countries like Brazil, Colombia, and Peru, also face yellow fever risks, prompting vaccination requirements for travelers and ongoing public health initiatives.

5. Asia-Pacific

   • The Asia-Pacific region, while not traditionally known for yellow fever, is seeing an increasing demand for vaccines due to rising travel to endemic areas in Africa and South America.

4. Competitive Landscape

Key players in the yellow fever vaccines market include:

1. Sanofi Pasteur

   • Sanofi Pasteur is the leading manufacturer of the yellow fever vaccine, offering the YF-VAX vaccine, which is the most commonly used live-attenuated yellow fever vaccine worldwide. The company is actively involved in global vaccination campaigns and has a strong market presence.

2. GlaxoSmithKline (GSK)

   • GSK is another major player in the vaccine market, offering the Sanofi-GSK Yellow Fever Vaccine in partnership with Sanofi. GSK is involved in manufacturing and distributing yellow fever vaccines globally.

3. Instituto Butantan

   • Based in Brazil, Instituto Butantan is a key supplier of yellow fever vaccines for the Brazilian population and other parts of Latin America. It is also involved in the production of vaccines for global organizations like the WHO.

4. Chinese National Pharmaceutical Group (Sinopharm)

   • Sinopharm is a major manufacturer and distributor of vaccines, including yellow fever vaccines, primarily serving regions in Asia and Africa.

5. Bharat Biotech

   • Bharat Biotech is an emerging player in the global vaccine market, including yellow fever vaccines. The company manufactures the BRYVAX yellow fever vaccine, which is being utilized in several regions for immunization programs.

5. Market Forecast and Future Outlook

The yellow fever vaccines market is expected to grow at a CAGR of 6.4% from 2025 to 2031. This growth is driven by the rising incidence of yellow fever outbreaks, the increasing awareness of vaccination, and the expansion of immunization programs in endemic regions. By 2031, the market is projected to reach USD 2.3 billion, fueled by ongoing public health initiatives and increased vaccine accessibility.